8-K: Evolus Reports Strong Q3 2024 Results with 22% Revenue Growth and European Approval for Estyme

Evolus announced a 22% increase in third-quarter revenue, reaching $61.1 million, and secured European approval for its Estyme injectable hyaluronic acid gels.

Summary

• Evolus reported a 22% increase in total net revenue for the third quarter of 2024, reaching $61.1 million, compared to $50.0 million in the same period of 2023.
• The company's year-to-date revenue growth is 33%.
• Evolus received approval for its Estyme injectable hyaluronic acid gels in the European Union and plans a full launch in the second half of 2025.
• The company's premarket approval application for Evolysse Form and Evolysse Smooth injectable HA gels is under review by the FDA, with approval and launch expected by September 2025.
• Evolus narrowed its full-year 2024 net revenue guidance to $260 million to $266 million, representing a year-over-year growth of 29% to 32%.
• The company reaffirmed its expectation of non-GAAP profitability in Q4 2024 and for the full year 2025.
• Evolus remains on track to achieve its projected total net revenue goal of at least $700 million and an operating margin of at least 20% by 2028.
• The company added over 600 new customer accounts in the quarter, bringing the total to nearly 14,500 since launch.
• The reorder rate among customers was approximately 70%.
• The Evolus Rewards consumer loyalty program has surpassed 1 million enrolled consumers.
• Total Evolus Rewards redemptions for the quarter hit an all-time high of over 190,000, with existing patients receiving repeat treatments at a rate of approximately 65%.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, European approval for Estyme, and reaffirmed guidance for profitability. However, the operating losses and cash burn temper the overall optimism.

Positives

• Evolus experienced strong revenue growth in Q3 2024, with a 22% increase compared to the same period last year.
• The company's year-to-date revenue growth of 33% indicates a strong upward trend.
• The European approval for Estyme expands Evolus's market reach and product portfolio.
• The Evolus Rewards program continues to grow, demonstrating strong customer loyalty and repeat business.
• The company is on track to achieve its long-term financial goals, including $700 million in revenue and a 20% operating margin by 2028.
• Evolus is expected to achieve non-GAAP profitability in Q4 2024 and for the full year 2025.

Negatives

• The company reported a loss from operations of $15.5 million for Q3 2024, compared to a loss of $7.7 million in the previous quarter.
• Non-GAAP loss from operations was $6.7 million in Q3 2024, compared to a $1.1 million income in the previous quarter.
• The decline in operating income quarter over quarter was primarily driven by typical seasonality of revenue.
• Cash and cash equivalents decreased from $93.7 million at June 30, 2024 to $85.0 million at September 30, 2024.

Risks

• The company's future performance is subject to uncertainties related to customer and consumer adoption of Jeuveau and Evolysse.
• Evolus faces competition and market dynamics that could impact its growth.
• The company's ability to successfully launch and commercialize its products in new markets, including the Evolysse HA gels in the U.S., is not guaranteed.
• Evolus relies on Symatese to achieve regulatory approval for the Evolysse HA gel line in the U.S.
• Unfavorable global economic conditions and their impact on consumer discretionary spending could affect the company's performance.
• The company's ability to fund future operations or obtain financing is subject to risk.

Future Outlook

Evolus expects to achieve positive non-GAAP operating income in Q4 2024 and for the full year 2025, and projects total net revenue of at least $700 million by 2028 with an operating margin of at least 20%.

Management Comments

• David Moatazedi, President and Chief Executive Officer, stated that the third quarter results underscore the momentum the company has been building throughout the year.
• He also mentioned that the company continues to deliver growth at multiples above the market, validating their performance beauty approach in the medical aesthetics industry.
• Moatazedi noted that Jeuveau resonates with a younger generation of consumers, as demonstrated by the recent achievement of over one million total consumers enrolled in their loyalty program.

Industry Context

Evolus is operating in the competitive medical aesthetics industry, focusing on neurotoxins and injectable hyaluronic acid gels. The company's strategy of targeting a younger demographic and building a strong loyalty program is aimed at differentiating itself from competitors. The European approval for Estyme positions Evolus as a key player in that market, and the upcoming launch of Evolysse in the U.S. is expected to further strengthen its market position.

Comparison to Industry Standards

• Evolus's 22% revenue growth in Q3 2024 is significantly higher than the estimated growth rate of the aesthetic neurotoxin market, indicating strong market share gains.
• The company's focus on a younger demographic and a cash-pay model differentiates it from competitors like Allergan (makers of Botox) and Galderma (makers of Dysport), which have a broader customer base.
• The achievement of over one million members in the Evolus Rewards program demonstrates a high level of customer engagement, which is a key competitive advantage.
• The approval of Estyme in the European Union positions Evolus as one of only five companies in Europe with both a neurotoxin and injectable HA gel line, giving it a competitive edge over companies that only offer one product type.
• The company's projected revenue of at least $700 million by 2028 and operating margin of at least 20% are ambitious targets that, if achieved, would place Evolus among the leading companies in the aesthetics market.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and European approval.
• Employees may be motivated by the company's positive performance and future growth prospects.
• Customers will benefit from the expanded product portfolio and continued innovation.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company as a lower risk due to its improved financial performance.

Next Steps

• Evolus will launch an experience program for Estyme in the European Union immediately.
• The company will prepare for the full launch of Estyme in Europe in the second half of 2025.
• Evolus will continue to work with the FDA on the approval of Evolysse Form and Smooth injectable HA gels.
• The company will prepare for the launch of Evolysse in the U.S. by September 2025.
• Evolus will continue to expand its product portfolio and market presence.
• The company will host a conference call and live webcast to discuss the financial results.

Key Dates

Keywords

Evolus, Jeuveau, Estyme, Evolysse, Hyaluronic Acid, Neurotoxin, Aesthetics, Revenue, Profitability, FDA, European Union, Loyalty Program